Evidence of Tiotropium in asthma
Revista Ciencia y Salud / eISSN: 2215-4949 / https://revistacienciaysalud.ac.cr/ojs

Vol. 5 No. 3 (2021)Artículos

Vol. 5 No. 3 (2021)

Evidence of Tiotropium in asthma

Artículos

PDF (Español (España))
HTML (Español (España))

Keywords

Asthma
Tiotropium bromide
Tiotropium
Muscarinic receptor antagonists
Bronchodilator

How to Cite

Yagua Velasquez, S. V., & Solano Vega, L. D. (2021). Evidence of Tiotropium in asthma. Revista Ciencia Y Salud, 5(3), Pág. 42–51. https://doi.org/10.34192/cienciaysalud.v5i3.281

Abstract

Asthma is a chronic disease with a significant disease burden and many patients fail to control the disease despite recommended medical therapy.19 The long-term goals of asthma management include achieving good control of symptoms, minimizing risk asthma exacerbations, reduce hospitalizations, use of rescue medication, airflow limitation and side effects, as well as allow normal levels of activity.29 According to the Global Initiative for Asthma (GINA) guidelines , asthma management is based on a cornerstone of inhaled corticosteroid therapy (ICS), supplemented with complementary therapies for those with poor or deteriorating disease control.1 Tiotropium, a long-acting anticholinergic bronchodilator that is administered once a day, it is indicated for the treatment of chronic obstructive pulmonary disease (COPD) for more than a decade and has recently been approved in several countries for the treatment of asthma.18

 

https://doi.org/10.34192/cienciaysalud.v5i3.281
PDF (Español (España))
HTML (Español (España))
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2021 Stephanie Veronica Yagua Velasquez, Luis Diego Solano Vega

Downloads